✨
AI Summary
- GSK bolsters its obesity strategy; Novo Nordisk leads in early oral obesity drugs.
- Roche's support for Switzerland is strained; Hengrui and BMS form R&D alliance.
- PCSK9 drug Lerochol launches in the US at a lower direct cost.